<DOC>
	<DOCNO>NCT01447043</DOCNO>
	<brief_summary>Retrospective , non-interventional , observational multi-center field study . Patients diagnose wet Age-related macular degeneration ( wAMD ) start treatment ranibizumab January 1 , 2009 August 31 , 2009 must consecutively screen , eligible , enrolled . Patients follow maximum August 31 , 2011 . Switch Anti vascUlar endothelial growth factor ( anti VEGF ) treatment document follow . For patient , demographic , medical history , administer treatment , result ocular visual assessment test ( available ) document .</brief_summary>
	<brief_title>Study Assess Effectiveness Existing Anti vascUlar Endothelial Growth Factor ( Anti VEGF ) Patients With Wet Age-related Macular Degeneration ( wAMD ) ( AURA )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Diagnosis wet agerelated macular degeneration Start Anti vascUlar endothelial growth factor ( anti VEGF ) therapy ranibizumab January 1 , 2009 August 31 , 2009 Informed consent form sign , require Participation investigational study antiVEGF therapy ( start August 31 , 2011 ) involve treatment drug medical device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>retrospective study</keyword>
</DOC>